The End of Cheaper Tirzepatide: What It Means for Patients
The Food and Drug Administration (FDA) recently declared that the shortage of branded tirzepatide is over. This decision has significant implications for patients and compounding pharmacies. For patients like Willow Baillies, who relied on compounded, cheaper versions of the drug to manage weight lo